ARM

@alliancerm

ARM is the international advocate for gene therapy, cell therapy, & tissue engineering.

Washington, DC
Vrijeme pridruživanja: svibanj 2011.

Tweetovi

Blokirali ste korisnika/cu @alliancerm

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @alliancerm

  1. Prikvačeni tweet
    21. sij

    Couldn't make it to the 2020 Cell & Gene Therapy State of the Industry Briefing? Video recordings are now available on ARM's YouTube page:

    Poništi
  2. proslijedio/la je Tweet
    prije 16 sati

    Together with and UKIS2, we have invested £2.5m seed funding to launch Ikarovec to further develop novel gene therapies for . Learn more here:

    Poništi
  3. proslijedio/la je Tweet
    Poništi
  4. proslijedio/la je Tweet

    NEWS: We've dosed the 1st patient in a Phase 1 study using AAV for the treatment of congestive heart failure. Thanks to Dr. Tim Henry and the team! Read more at .

    Poništi
  5. proslijedio/la je Tweet
    4. velj

    Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO902 Gene Therapy in Patients with Overactive Bladder: Urovant Sciences Nasdaq UROV announced today the publication of the safety and efficacy results of URO902…

    Poništi
  6. proslijedio/la je Tweet
    4. velj

    Passage ended 2019 with $158.9 million in the bank and now expects its phase 1/2 gangliosidosis trial to kick off in the second half of 2020, with trials for the dementia and Krabbe candidates to follow in the first half of 2021

    Poništi
  7. 3. velj

    A robust clinical pipeline, strong global financings, and the potential for immense benefit to patients: ARM CEO shares her thoughts on the state of the regenerative medicine sector in 2019 and the outlook for 2020 –

    Poništi
  8. proslijedio/la je Tweet
    3. velj

    [PRESS RELEASE] Upon completion of the transaction, MaSTherCell and Catalent will position the new entity as a leading cell therapy platform in the industry! MaSTherCell’s Press Release: / More info on Catalent's website:

    Poništi
  9. 30. sij

    Managing Uncertainty In Drug Value: Outcomes-Based Contracting Supports Value-Based Pricing –

    Poništi
  10. proslijedio/la je Tweet

    Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement

    Poništi
  11. proslijedio/la je Tweet
    27. sij
    Poništi
  12. proslijedio/la je Tweet
    29. sij

    $CABA’s lead candidate, DSG3-CAART, has been granted Orphan Drug Designation by the for the treatment of pemphigus vulgaris (PV)

    Poništi
  13. 30. sij

    Penn researchers identify cancer cell defect driving resistance to therapy –

    Poništi
  14. 30. sij

    Hitachi Chemical Advanced Therapeutics Solutions Announces Opening of Its New Facility Designed to Manufacture Commercial Cell and Gene Therapies:

    Poništi
  15. proslijedio/la je Tweet
    29. sij

    Rare disease biotech Passage Bio nabs Deerfield veteran as CEO

    Poništi
  16. proslijedio/la je Tweet
    29. sij

    PRESS RELEASE: Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD). Learn more:

    Poništi
  17. proslijedio/la je Tweet
    28. sij

    Today the Marketing Authorization Application for our second therapy was validated for review by the European Medicines Agency

    Poništi
  18. proslijedio/la je Tweet
    29. sij

    With new rules, FDA aims to spark competition, lower prices for expensive gene therapies via

    Poništi
  19. proslijedio/la je Tweet
    29. sij

    Novartis said approximately 200 patients have been treated with Zolgensma, a lifesaving gene therapy for infants and the world’s most expensive medicine.

    Poništi
  20. proslijedio/la je Tweet
    29. sij

    Very sad news for the evidence-based treatment of patients and for companies focussed on ethical research. U.S. judge rejects FDA bid to shut down stem cell clinics, dealing blow to regulators

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·